Batavia Biosciences

Leiden, Netherlands Founded: 2010 • Age: 16 yrs Acquired By CJ CheilJedang
Biologics CDMO offering proprietary process development technologies for the development of recombinant proteins, vaccines and gene therapy products

About Batavia Biosciences

Batavia Biosciences is a Healthcare company based in Leiden (Netherlands) founded in 2010 by Chris Yallop and Menzo Havenga, and was acquired by CJ CheilJedang in November 2021. Biologics CDMO offering proprietary process development technologies for the development of recombinant proteins, vaccines and gene therapy products. The company has 11 employees. Its chief executive, as recorded, is Menzo Havenga. Batavia Biosciences offers products and services including Viral Vectors, Viral Vaccines, and HIP-Vax Technology. Its focus areas include Biopharma Outsourcing, CDMO and Biologics. Its legal entity is BATAVIA BIO PROCESSING LIMITED.

Company details

Batavia Biosciences is a CDMO engaged in the development of biopharmaceutical products such as proteins, antibodies, vaccines and viral vectors. They have a portfolio of technologies for improving product yield (STEP), to reduce process development time (SIDUS, SCOUT) and for improving product stability. Their STEP technology is a plasmid based expression platform that enables rapid mammalian CHO cell line generation and improved protein expression. Batavia claims that the STEP platform can offer up to 10-fold increase in protein expression and the stable cell clones can be generated in 14 weeks. They also have a transient production technology that can be used for producing clinical material (proteins) faster. The company claims to have expertise in upstream (mammalian, microbial and insect based platforms) and downstream processing, clinical and commercial manufacturing and also in DNA cloning and mammalian cell line generation.

  • Headquarters Leiden, Netherlands
  • Employees 11
  • Founders Chris Yallop, Menzo Havenga
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    โ€ขโ€ขโ€ขโ€ขโ€ขโ€ขโ€ขโ€ข
  • Website bataviabiosciences.com
  • Social LinkedIn X
  • Acquired by CJ CheilJedang (Nov 2021)
  • Legal Name Batavia Bio Processing Limited
Key Metrics

Products & Services of Batavia Biosciences

Batavia Biosciences offers a comprehensive portfolio of products and services, including Viral Vectors, Viral Vaccines, and HIP-Vax Technology.

Viral Vectors
Biotech Products

Development and manufacturing for gene therapy and delivery tools.

Viral Vaccines
Biopharmaceuticals

Process development for vaccine production and applications.

HIP-Vax Technology
Manufacturing Platforms

Platform for efficient polio and other vaccine manufacturing processes.

Funding Insights of Batavia Biosciences

  • Total Rounds 8
  • Last Round Grant โ€” $444,292
  • First Round $12M

    (Jun 2016)

  • Investors Count 3

All 8 funding rounds of Batavia Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2023$444,292Grantโ€“โ€“
Sep 2019$6.5MGrantโ€“โ€“
Jul 2019$2.2MGrantโ€“โ€“
Feb 2019$13.2MGrantโ€“โ€“
Jan 2019$889,938Grantโ€“โ€“
Jan 2018$1.18MGrantโ€“โ€“
Jan 2018$4MGrantโ€“โ€“
Jun 2016$12MGrantโ€“โ€“
Valuation history

4 investors in total: 4 institutional.

Investors in Batavia Biosciences

Batavia Biosciences has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Gates Foundation, Path and European Union.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Charitable foundation investments on poverty reduction and healthcare
2000gatesfoundation.orgSeattle, United States
Global health solutions are developed and delivered to enhance outcomes.
1977path.orgUnited States
CJ CheilJedang is engaged in food and bio industries.
cj.co.krSeoul, South Korea
Premium access

Investor details for Batavia Biosciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Batavia Biosciences

31 people are tracked at Batavia Biosciences (11 in leadership, 20 in team); the tracked headcount is 11.

NameRoleGroup
Chris Yallop
Co-FounderLeadership
Menzo Havenga
CEO & FounderLeadership
Marty Stork
Chief Human Resources OfficerLeadership
Jeffrey Kovacs
Head Of BD - USLeadership
David Foster
Chief Scientific OfficerLeadership
Pablo Mendes de León
CFOLeadership
Ingrid van Aarle
Human Resources DirectorLeadership
Pieter-Jan Vos
Director Business DevelopmentLeadership
Marieke Willemsen
Project DirectorLeadership
Wendy Laird
Director, Business DevelopmentLeadership
Carola Jüstel
Senior Director Business DevelopmentLeadership
Fiona Hancox
Functional Support TechnicianTeam
Jordy K.
QC SpecialistTeam
Fouad El Khayari
Quality Assurance OfficerTeam
Annemiek Hildebrand-Bosman
QA ManagerTeam
Assia Bouabda
QA OfficerTeam
Hans Verdurmen
Scientist USP Process DevelopmentTeam
Jochem Pronk
Sr. Scientist DSPTeam
A. Mecit Gokce
Senior ScientistTeam
David Mourette
Business ControllerTeam

11 more people are available in the full profile.

Premium access

Complete people profiles for Batavia Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Batavia Biosciences

4 dated milestones of Batavia Biosciences across 13 years, from founding to its latest funding, stage changes and deals.

  1. Founded Batavia Biosciences is founded.
  2. Funding First funding round of $12.0M.
  3. Exit Acquired by CJ CheilJedang.
  4. Funding Latest funding round, Grant, of $444K.

Web traffic of Batavia Biosciences

The website of Batavia Biosciences (bataviabiosciences.com) receives about 6.8K visits a month and ranks #3,268,559 among all websites worldwide, #4,297 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    6.8K

    ▲ 8.8% vs previous month

  • Unique visitors
    2.6K

    per month

  • Global rank
    #3,268,559

    among all websites

  • Category rank
    #4,297

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Batavia Biosciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
astellas.com
100%
170.7K#288,207View details
interpulse.nl
36%
#8,540,819View details
vicotx.com
36%
2.5K#6,930,770View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track โ€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • โœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • โœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • โœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Batavia Biosciences

Premium access

Complete news archive for Batavia Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Batavia Biosciences

Batavia Biosciences was founded in 2010 and raised its 1st funding round 6 years after it was founded.

Batavia Biosciences is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.

Menzo Havenga is the CEO of Batavia Biosciences, as recorded in our data. They have also founded this company.

Batavia Biosciences has 11 employees.

Batavia Biosciences is a CDMO engaged in the development of biopharmaceutical products such as proteins, antibodies, vaccines and viral vectors. They have a portfolio of technologies for improving product yield (STEP), to reduce process development time (SIDUS, SCOUT) and for improving product stability. Their STEP technology is a plasmid based expression platform that enables rapid mammalian CHO cell line generation and improved protein expression. Batavia claims that the STEP platform can offer up to 10-fold increase in protein expression and the stable cell clones can be generated in 14 weeks. They also have a transient production technology that can be used for producing clinical material (proteins) faster. The company claims to have expertise in upstream (mammalian, microbial and insect based platforms) and downstream processing, clinical and commercial manufacturing and also in DNA cloning and mammalian cell line generation.

Batavia Biosciences offers Viral Vectors, Viral Vaccines, and HIP-Vax Technology.

Batavia Biosciences has 4 investors. Key investors include Gates Foundation, Path, European Union, and CJ CheilJedang.

Batavia Biosciences operates through Batavia Bio Processing Limited.

Yes. Batavia Biosciences was acquired by CJ CheilJedang in November 2021.

Explore millions of companies โ€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals โ€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available